Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.69 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065472 | 0.84 | MCL1 (0.71) | MCL1GPR35KDM4EHPGDGAA | |
| SCHEMBL28209634 | 0.83 | NPC1 (0.64) | MCL1KDM4ESMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL720361 | 0.82 | POLB (0.49) | MCL1GPR35KDM4EHPGDGAA | |
| SCHEMBL4615856 | 0.81 | MCL1 (1.00) | MCL1GPR35KDM4EHPGDGAA | |
| SCHEMBL4310466 | 0.81 | MCL1 (0.67) | MCL1GPR35KDM4EHPGDGAA | |
| SCHEMBL3617512 | 0.81 | MCL1 (0.67) | MCL1GPR35KDM4EHPGDGAA | |
| SCHEMBL10735951 | 0.80 | MCL1 (0.65) | MCL1GPR35KDM4EHPGDGAA | |
| SCHEMBL28217436 | 0.80 | NPC1 (0.58) | MCL1GAASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1474090 | 0.80 | MEN1 (0.60) | KDM4EHPGDGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL12660569 | 0.79 | KDM4E (0.51) | MCL1KDM4EHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006715-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-5767133-A | Secondary amines as antidiabetic and antiobesity agents | PFIZER INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0703911-B1 | SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | PFIZER (US) | 1997-07-02 | — | — | EP | disclosed |
| US-5627200-A | β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia | PFIZER INC (US) | 1997-05-06 | — | — | US | disclosed |
| CN-1129443-A | Secondary amines as antidiabetic and antiobesity agents | PFIZER (US) | 1996-08-21 | — | — | CN | disclosed |
| EP-0703911-A1 | SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | PFIZER (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994029290-A1 | SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | PFIZER INC. (US) | 1994-12-22 | — | — | WO | disclosed |